Close2U: An App for Monitoring Cancer Patients with Enriched Information from Interaction Patterns

Navarro-Alamán, Javier; Lacuesta, Raquel; García‐Magariño, Iván; Gallardo, Jesús; Ibarz, Elena; Lloret, Jaime

doi:10.1155/2020/3057032

Cited by 6 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many apps did not support a specific cancer treatment (23/73, 32%) [ 46 , 51 , 53 , 62 , 71 - 74 , 83 , 84 , 86 , 88 , 93 , 95 , 98 , 99 , 104 , 105 , 108 , 112 , 117 , 118 , 121 , 124 , 126 ]. The most frequent treatment specifications were chemotherapy (15/73, 21%) [ 47 , 50 , 55 , 63 , 64 , 70 , 78 , 85 , 87 , 101 , 110 , 114 - 116 , 119 , 127 , 129 , 131 ], oral anticancer treatments (13/73, 18%) [ 9 , 48 , 52 , 56 - 58 , 65 , 76 , 80 , 82 , 90 , 91 , 94 , 111 , 122 , 128 ], radiotherapy (3/73, 4%) [ 54 , 92 , 120 ], and others (8/73, 11%) [ 12 , 16 , 45 , 59 , 60 , 66 - 69 , …”

Section: Resultsmentioning

confidence: 99%

“…mHealth users can be patients, clinicians, a broader pool of health care professionals (HCPs), or different combinations of users. Most commonly, apps are designed for both patients and clinicians (42/73, 58%) [ 12 , 16 , 48 - 55 , 58 , 59 , 61 , 63 , 66 , 67 , 69 , 75 , 77 , 84 - 86 , 89 , 91 - 94 , 96 , 98 , 100 , 101 , 104 - 106 , 108 , 110 , 112 - 116 , 119 , 120 , 122 - 125 , 127 - 129 , 131 ], who typically access different interfaces and functionalities (eg, self-reporting function for patients, web-based dashboards with overview of patient activity for the clinicians). Only 32% (23/73) apps [ 8 , 47 , 60 , 64 , 65 , 68 , 70 - 73 , 76 , 78 - 83 , 87 , 88 , 95 , 97 , 99 , 102 , 103 , 107 , 111 , 121 , 126 , 130 ] were designed for exclusive patient use.…”

Section: Resultsmentioning

confidence: 99%

“…The selected studies assessed mHealth impact using a wide range of outcome metrics analyzed using the taxonomy by Dodd et al [ 42 ]. Outcomes most recurrently fall under the Life impact area, with 73 outcomes in the Delivery of Care outcome domain [ 8 , 9 , 12 , 16 , 45 , 46 , 48 - 55 , 57 - 63 , 65 , 67 , 70 , 71 , 73 - 87 , 90 - 92 , 94 - 104 , 107 - 116 , 119 - 122 , 128 - 131 ], 37 in Global quality of life [ 8 , 57 , 60 , 62 , 64 , 65 , 68 , 72 , 75 , 78 , 84 , 86 , 88 - 91 , 93 , 97 , 101 , 103 , 105 , 106 , 112 , 114 , 115 , 119 - 121 , 123 - 131 ], 16 in Emotional functioning and well-being [ 66 , 70 , 77 , 83 , 89 , 90 , 93 , 106 , 115 ,…”

Section: Resultsmentioning

confidence: 99%

“…mHealth users can be patients, clinicians, a broader pool of health care professionals (HCPs), or different combinations of users. Most commonly, apps are designed for both patients and clinicians (42/73, 58%)[12,16,[48][49][50][51][52][53][54][55]58,59,61,63,66,67,69,75,77,[84][85][86]89,[91][92][93][94]96,98,100,101,[104][105][106]108,110,[112][113][114][115][116]119,120,[122][123][124][125][127][128][129]…”

mentioning

confidence: 99%

“…55,57-63,65,67,70,71,73-87,90-92, 94-104,107-116,119-122,128-131], 37 in Global quality of life[8,57,60,62,64,65,68,72,75,78,84,86,[88][89][90][91]93,97,101,103,105,106,112,114,115,[119][120][121][123][124][125][126][127][128][129][130][131], 16 in Emotional functioning and well-being[66,70,77,83,89,90,93,106,115,119,[125][126][127][128]…”

mentioning

confidence: 99%

See 4 more Smart Citations

Evaluating Barriers and Facilitators to the Uptake of mHealth Apps in Cancer Care Using the Consolidated Framework for Implementation Research: Scoping Literature Review

Ardito¹,

Golubev²,

Ciani³

et al. 2023

JMIR Cancer

View full text Add to dashboard Cite

Background Mobile health (mHealth) solutions have proven to be effective in a wide range of patient outcomes and have proliferated over time. However, a persistent challenge of digital health technologies, including mHealth, is that they are characterized by early dropouts in clinical practice and struggle to be used outside experimental settings or on larger scales. Objective This study aimed to explore barriers and enablers to the uptake of mHealth solutions used by patients with cancer undergoing treatment, using a theory-guided implementation science model, that is, the Consolidated Framework for Implementation Research (CFIR). Methods A scoping literature review was conducted using PubMed (MEDLINE), Web of Science, and ScienceDirect databases in March 2022. We selected studies that analyzed the development, evaluation, and implementation of mHealth solutions for patients with cancer that were used in addition to the standard of care. Only empirical designs (eg, randomized controlled trials, observational studies, and qualitative studies) were considered. First, information on the study characteristics, patient population, app functionalities, and study outcomes was extracted. Then, the CFIR model was used as a practical tool to guide data collection and interpretation of evidence on mHealth uptake. Results Overall, 91 papers were included in the data synthesis. The selected records were mostly randomized controlled trials (26/91, 29%) and single-arm, noncomparative studies (52/91, 57%). Most of the apps (42/73, 58%) were designed for both patients and clinicians and could be used to support any type of cancer (29/73, 40%) and a range of oncological treatments. Following the CFIR scheme (intervention, outer setting, inner setting, individuals, process), multistakeholder co-design, codevelopment, and testing of mHealth interventions were identified as key enablers for later uptake. A variety of external drivers emerged, although the most relevant outer incentive fostering mHealth use was addressing patient needs. Among organizational factors likely to influence technology uptake, interoperability was the most prominent, whereas other providers’ dimensions such as managerial attitudes or organizational culture were not systematically discussed. Technology-related impediments that could hamper the use of mHealth at the individual level were considered least often. Conclusions The hype surrounding mHealth in cancer care is hindered by several factors that can affect its use in real world and nonexperimental settings. Compared with the growing evidence on mHealth efficacy, knowledge to inform the uptake of mHealth solutions in clinical cancer care is still scarce. Although some of our findings are supported by previous implementation research, our analysis elaborates on the distinguishing features of mHealth apps and provides an integrated perspective on the factors that should be accounted for implementation efforts. Future syntheses should liaise these dimensions with strategies observed in successful implementation initiatives.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…mHealth users can be patients, clinicians, a broader pool of health care professionals (HCPs), or different combinations of users. Most commonly, apps are designed for both patients and clinicians (42/73, 58%)[12,16,[48][49][50][51][52][53][54][55]58,59,61,63,66,67,69,75,77,[84][85][86]89,[91][92][93][94]96,98,100,101,[104][105][106]108,110,[112][113][114][115][116]119,120,[122][123][124][125][127][128][129]…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Evaluating Barriers and Facilitators to the Uptake of mHealth Apps in Cancer Care Using the Consolidated Framework for Implementation Research: Scoping Literature Review

Ardito¹,

Golubev²,

Ciani³

et al. 2023

JMIR Cancer

View full text Add to dashboard Cite

show abstract

Agile Software Engineering in Medical Environments: Challenges and Opportunities

Saoiabi,

Kharmoum,

Elasri

et al. 2024

Lecture Notes in Networks and Systems

View full text Add to dashboard Cite

Fabry App: the value of a portable technology in recording day-to-day patient monitored information in patients with Fabry disease

D’Amore,

Mckie,

Fahey

et al. 2024

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background Fabry disease is a rare inherited disorder resulting from deficient α-galactosidase A enzyme activity. Common disease manifestations are sweating abnormalities, neuropathic pain, gastrointestinal symptoms and fatigue. Challenges are faced by health care professionals in evaluating symptom burden in the current clinical setting, and the demand for alternative methods for monitoring disease-specific symptoms has seen an acceleration in recent years. Smartphone technologies offer the potential for continuity of care and surveillance. As a part of a quality improvement project, a disease specific app was developed in collaboration with a software company (Health Touch Ltd) and made available for patient use in May 2018. The Fabry mobile app records five categories: pain, gastrointestinal symptoms, sweating, activity levels, medications. Fabry disease patients with gastrointestinal and pain symptoms attending the Lysosomal Storage Disorders Unit of the Royal Free London NHS Foundation Trust were reviewed to assess eligibility and invited to download the app for recording their symptoms (activity, sweating, pain and gastrointestinal) and medications. Patient-generated data were transmitted to a secure website for clinicians to review. Results One-hundred and thirty-nine symptomatic Fabry disease patients who had a smartphone (iPhone or android) were invited to download the app. Sixty-seven patients (26 males and 41 females; median age, 49 years [range, 20–81]) downloaded and tracked the Fabry App at least once. The median frequency of use per patient was 6 (range, 1–629). Pain in the hands and abdominal pain were significantly higher (p = 0.009 and p = 0.007, respectively) in patients with classic phenotype compared with patients with non-classic phenotypes. Conclusions We demonstrated the feasibility and acceptability of a smartphone app to facilitate the remote assessment and monitoring of Fabry disease symptom burden on a daily/weekly basis, as an alternative to the current standard of care that requires patients to recall their symptoms during 6 to 12 monthly annual clinic visits. Patients who were more likely to use the app had greater disease burden. This innovation has the potential to assess disease progression, early therapeutic intervention, thereby decreasing the burden of morbidity and mortality among Fabry patients, and to record long-term effects of Fabry-specific therapies.

show abstract

Close2U: An App for Monitoring Cancer Patients with Enriched Information from Interaction Patterns

Cited by 6 publications

References 18 publications

Evaluating Barriers and Facilitators to the Uptake of mHealth Apps in Cancer Care Using the Consolidated Framework for Implementation Research: Scoping Literature Review

Evaluating Barriers and Facilitators to the Uptake of mHealth Apps in Cancer Care Using the Consolidated Framework for Implementation Research: Scoping Literature Review

Agile Software Engineering in Medical Environments: Challenges and Opportunities

Fabry App: the value of a portable technology in recording day-to-day patient monitored information in patients with Fabry disease

Contact Info

Product

Resources

About